Oxford Biomedica

Last night our Oxford team came together at OXB’s end of year celebration! The team took time to relax, connect, and share some holiday cheer while celebrating a year of achievement. A highlight of the evening? Seeing our Chief Business Officer, Sébastien Ribault, briefly trade strategic plans for the DJ deck. Who knew business and music could harmonise so well? A huge thank you to everyone who helped organise such a wonderful evening and to all our colleagues who brought the energy to make it a celebration to remember. Here’s to another fantastic year ahead, driven by the amazing people who make OXB such a unique and inspiring place to be. #TeamOXB #EndOfYearCelebration #LeadershipInTune #CDMO #OXB

As we conclude our 12 Days of OXB celebrations, on the twelfth day, we’re pleased to share a special message from our CEO, Dr. Frank Mathias, reflecting on the last 𝘁𝘄𝗲𝗹𝘃𝗲 months of achievements and milestones at OXB. Thank you for joining us on our festive campaign. From everyone at OXB, we wish you a restful holiday season and look forward to continued collaboration in the coming year! #OXB12Days #OXB #CDMO

On day eleven of our festive campaign, we’re spotlighting the 𝗲𝗹𝗲𝘃𝗲𝗻 dedicated leaders who guide OXB’s talented teams worldwide. From senior management to site leadership, they bring decades of experience, with most contributing 20–25 years in the CDMO industry and our CEO leading the way with 35 years of expertise. This depth of knowledge drives the agility, innovative thinking, and tailored solutions that consistently deliver success for our clients and their life-changing therapies But they’re just one part of the story. Every success is built on the dedication and collaboration of our talented teams across OXB, whose efforts drive our mission forward. Meet the leadership team driving innovation at OXB: https://lnkd.in/eXpgNJBZ Stay tuned for tomorrow’s final post—it's a special one! #OXB12Days #OXBTeam #Collaboartion #LeadershipMatters #CDMO

On day ten of our festive campaign, we’re reflecting on an important part of what we do: building long-lasting partnerships with our clients. This year, we celebrate over 𝘁𝗲𝗻 years of collaboration with our longest-standing client!   At OXB, our clients choose to stay with us because we: 🔹 Understand their needs and priorities 🔹 Tailor our support to meet their unique challenges 🔹 Actively listen to feedback and continuously improve our services 🔹 Maintain open and consistent communication throughout the entire process If you’re looking for a partner committed to your success, get in touch with us at 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝗶𝗻𝗴@𝗼𝘅𝗯.𝗰𝗼𝗺. Join us tomorrow for day 11!   #OXB12Days #ClientPartnerships #Collaboration #LongTermSuccess #CDMO

On day nine of our festive campaign, we’re proud to showcase a 𝟵-fold improvement in lentiviral vector (LV) titres, achieved through OXB’s innovative technologies! This advancement optimises processes for LV-based therapies, helping to deliver better outcomes for patients who rely on these life-changing treatments.    Discover how this achievement is advancing LV-based therapies: https://lnkd.in/eC_sd4XE    Check back tomorrow for day 10!    #OXB12Days #Innovation #LentiviralVectors #ViralVectors #CDMO

It’s day eight of our festive campaign and we’re celebrating our Oxford manufacturing facilities, home to 𝗲𝗶𝗴𝗵𝘁 state-of-the-art GMP suites! With six vector substance suites and two for fill and finish, they are purpose-built to offer flexibility and scale to meet our clients’ viral vector development and manufacturing needs with precision.    Learn more about our capabilities here: https://lnkd.in/ez2sgmKz    Don’t miss day 9 tomorrow!    #OXB12Days #CellandGeneTherapy #Manufacturing #CDMO

On day seven of our festive campaign, we’re spotlighting our 𝘀𝗲𝘃𝗲𝗻 bioprocessing and manufacturing facilities across the globe. Strategically located in the UK, France, and the US, these facilities enable us to support our clients in delivering innovative cell and gene therapies to patients worldwide.    Learn more about our facilities here: https://lnkd.in/eDRech5E    Day 8 is just around the corner—stay tuned!    #OXB12Days #GlobalReach #CDMO 

Day six of our festive campaign is dedicated to the successful inspections our OXB sites have received from 𝘀𝗶𝘅 regulatory agencies worldwide: FDA, MHRA, EMA, ANVISA, PMDA and ANSM – enabling us to help our clients deliver life changing cell and gene therapies to patients around the world. Don’t miss out on day 7 tomorrow! #OXB12Days #CDMO #ViralVectors #CellAndGeneTherapy #GeneTherapy 

Its day five of our festive campaign and we’re highlighting 𝗳𝗶𝘃𝗲 reasons why you should choose OXB’s LentiVector™ platform to rapidly bring your lentiviral vector (LV) therapy to market: 1. Extensive track record with over 25+ years of expertise developing LV processes  2. Large suite of analytical methods with over 90% performed in-house  3. Access to leading technologies to improve LV quality, potency, safety and packaging capacity  4. Multiple timeline options (LentiVector™ platform or non-platform approach) for maximum flexibility from project initiation to GMP release  5. Robust process and agile service offering with option to tech transfer Visit https://lnkd.in/ecvUzXzC to find out more. #OXB12Days #LentiviralVectors #ViralVectors #Innovation #CellAndGeneTherapy #CDMO 

On the fourth day of our festive campaign, we shine a light on the TetraVecta™ system—our 𝟰𝘁𝗵-generation lentiviral vector delivery system.  This next-generation innovation can significantly enhance the development and manufacturing of safer and more effective lentiviral vector-based therapies through improved quality, potency and packaging capacity. View our latest TetraVecta™ System poster to discover how this new technology is paving the way for genuine plug and play manufacturing: https://lnkd.in/ep53JA_H    Join us tomorrow for day 5!    #OXB12Days #LentiviralVectors #ViralVectors #Innovation #CellAndGeneTherapy